Clinical trials: Multiple Sclerosis, Progressive
Multiple Sclerosis
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
The management of MS-patients requires treatment with immune-modifying or immune-suppressive agents to prevent new relapses and progression of disability.
- Trial name
- NCT01411514
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Claudio Gobbi
Primary Progressive Multiple Sclerosis
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients with primary progressive multiple sclerosis (PPMS).
- Trial name
- FUMAPMS (NCT02959658)
- Testing
- Dimethyl fumarate
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis
Multiple Sclerosis and Heavy Progressive Resistance Training
The purpose of the present investigation is to determine whether MS patients can tolerate and benefit from heavy progressive resistance training.
- Trial name
- NCT00381576
- Testing
- Resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 36 people
- Sponsor
- University of Aarhus
Multiple Sclerosis
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
- Trial name
- NCT02601885
- Testing
- ABT-555
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- DanNORMS (NCT04688788)
- Testing
- Rituximab, Ocrelizumab, Fexofenadine
- Where
- 11 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis
Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis
An open prospective study with multiple (every 6-12 months) intrathecal or intravenous injections of autologous MSC in patients with progressive forms of MS (secondary progressive, primary progressive or relapsing-progressive)…
- Trial name
- MSC-pMS (NCT04823000)
- Testing
- Mesenchymal Stem Cells (MSC)
- Volunteers
- 24 people
- Sponsor
- Hadassah Medical Organization
Multiple Sclerosis Acute and Progressive
Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis
1. use QoL assessments to check whether interventions have been as effective from the patient's point of view as from the clinician's, and to determine whether further action is required .
- Trial name
- NCT05029830
- Testing
- investigations like MRI..
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Multiple Sclerosis
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)
The study will use a multimodal therapeutic lifestyle intervention consisting of a study diet, stressing more vegetables and fruit, elimination of foods at greatest risk for food allergy, meditation, self massage, progressive…
- Trial name
- NCT01381354
- Testing
- Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Iowa
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Secondary Progressive Multiple Sclerosis
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study…
- Trial name
- NCT06292923
- Testing
- Foralumab
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Tiziana Life Sciences LTD
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis, Chronic Progressive
Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS
Due to their ubiquitary distribution, smartphones might serve as an easy way/ possibility to use feedback mechanism in an app-based intervention program to increase physical activity in Multiple Sclerosis (MS) patients.
- Trial name
- PIA (NCT03114293)
- Testing
- Smartphone App
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis
MUSCLE - Nordic Walking in MUltiple SCLErosis
The aim of the study is to analyze the effects of Nordic Walking and free walking in the clinical-functional, postural balance, motor control, muscular echographic quality, and gait analysis (pendulum gait mechanism), in people…
- Conditions
- Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MUSCLE (NCT05385731)
- Testing
- Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Leonardo A. Peyré-Tartaruga
Secondary Progressive Multiple Sclerosis (SPMS)
Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to assess the safety and efficacy of repeated intrathecal (IT) injection of NG01, autologous bone marrow derived human stromal cells, in treating Secondary Progressive Multiple Sclerosis (SPMS)…
- Trial name
- NCT06961383
- Testing
- NG01 - Autologous bone marrow derived human stromal cells, Sodium Chloride 0.9%
- Where
- 2 sites in United States, Israel
- Volunteers
- 45 people
- Sponsor
- NeuroGenesis Ltd.
Secondary Progressive Multiple Sclerosis
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
The purpose of this study is to compare expanded disability status scale, annualized relapse rate, Gad-enhanced brain lesions, and side effects after administration of rituximab and glatiramer acetate among patients with active…
- Trial name
- NCT03315923
- Testing
- Rituximab, Glatiramer Acetate
- Where
- Iran
- Volunteers
- 84 people
- Sponsor
- Isfahan University of Medical Sciences
Secondary Progressive Multiple Sclerosis
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
- Trial name
- NCT01181089
- Testing
- Baminercept
- Sponsor
- Biogen
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination.
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
- Trial name
- NCT05893225
- Testing
- Metformin Hydrochloride 850 mg Oral Tablet
- Where
- 5 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- University Hospital, Antwerp
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
- Trial name
- NCT03737812
- Testing
- elezanumab
- Where
- 37 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- AbbVie
Multiple Sclerosis, Chronic Progressive
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
- Trial name
- NCT01188811
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.